11 news items
MAIA Biotechnology (MAIA): Pioneering New Frontiers in NSCLC Treatment with THIO
BMRN
EXEL
GMAB
7 Jun 24
(ASCO) 2024 Annual Meeting, show a remarkable overall response rate (ORR) of 38% and a disease control rate (DCR) of 85% when THIO is paired
Decoding 12 Analyst Evaluations For Jazz Pharmaceuticals
JAZZ
5 Jun 24
', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Jazz Pharmaceuticals. This information provides
Reported Saturday, Jazz Pharmaceuticals Showcased Updated Survival Data From The HERIZON-BTC-01 Trial Of Zanidatamab In HER2-Positive Biliary Tract Cancer At ASCO 2024
JAZZ
3 Jun 24
, as of July 28, 2023, median duration of response (DOR) increased by two months from initial analysis to 14.9 months
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
JAZZ
1 Jun 24
duration of response (DOR) increased by two months from initial analysis to 14.9 months
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
JAZZ
30 May 24
Pharmacokinetic and Exposure-Response Analyses Supporting Individualized Dosing of Oxybate
zik77yi6rs7
JAZZ
29 May 24
response rate (cORR) by independent central review (ICR) and results were presented
gsqr vsz3rffdly8zhucedx579fjxwjufyu0yix1io477h3sjp586o
JAZZ
28 May 24
, Dan served as Senior Vice President of Sales and Marketing at ALZA Corporation, where he was responsible for its flagship pharmaceutical businesses
9599tg0bjhck7gni7kqao oplr3p2hc20g0766qvqw
AMGN
CASI
JAZZ
7 May 24
. Ligand is not responsible for, and has no role in, the development of such products or programs.
Ligand
jloo76z0t4qn54j2u8ve0nte29qqb2mlesu1zm6wk04afz0760ce9
JAZZ
2 May 24
, it signifies their response to recent developments related to Jazz Pharmaceuticals. This offers insight into analysts' perspectives on the current
soxfwrrtegzzz3d 3y4mvm8ymz3pgsdrvv
JAZZ
24 Apr 24
-based chemotherapy. The approval is based on overall response rate (ORR) and duration of response demonstrated in an open-label, monotherapy clinical
h5tphjk0v2529wckyzi2f5lfg8 jjia1wh4q14cu06spe5vq
JAZZ
10 Apr 24
Key Insights:
Action Taken: In response to dynamic market conditions and company
- Prev
- 1
- Next